

КЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ ОНКОЛОГИЯ

ЕЖЕКВАРТАЛЬНЫЙ НАУЧНО-ПРАКТИЧЕСКИЙ ЖУРНАЛ АССОЦИАЦИИ ОНКОЛОГОВ УЗБЕКИСТАНА

СБОРНИК ТЕЗИСОВ

XIX Республиканская научно-практическая конференция на тему:

«Современные технологии в диагностике и лечении опухолей».

Дата: 19-20 мая 2023 года
Место проведения: г. Хива



Абдукаримов У.Г., Саидов Г.Н., Ширинов М.М., Ососков А.В. Предварительные результаты внедрения технологии 3d стереотаксической биопсии опухолей молочных желез	89
Абдихакимов А.Н., Мирзамухамедов Х.К., Турдибеков Ш.М. Целесообразность скинтиграфического исследования костей скелета при раке молочной железы	89
Авезмуратова Г.А., Ахмедова С.М., Пулатов Д.А. Клинико морфологические изменение рака молочной железы при иммуногистохимическом типу	90
Авезмуратова Г.А., Пулатов Д.А. Изучения отдаленного постлечебного патоморфоза и степени злокачественности при раке молочной железы	90
Алимов А.К., Жуманиязов М.М. Оценка эффективности различных методов лечения у больных с местнораспространенным раком молочной железы	91
Алимходжаева Л.Т., Нишанов Д.А., Бозарова Л.М., Зиеведенова С.С. Клиническая значимость изменений рецепторного статуса в опухолях добавочной доли молочной железы	91
Alimhodjayeva L.T., Mirzayeva M., Zakirova L.T. The relationship between obesity and breast cancer subtypes	92
Alimkhodzhaeva L.T., Norbekova M.Kh. Metastatic breast cancer in men	93
Алимходжаева Л.Т., Мирзаева М. Оценка эффективности химиотерапии при редком гистологическом формы раке молочной железы на фоне метаболического синдрома у женщин	94
Аллаяров О.М., Джалолова Ф.М. Аёллар репродуктив абзоларининг сут беги ўсма касалликлари ривожланишига таъсири	94
Аллаяров О.М., Джалолова Ф.М., Абдурасулов Х. Эффективность таргетной терапии HER2/NEU позитивного рака молочной железы	95
Аминжонов Р.М., Бобоев Ш.Р. Оценка эффективности методов лечение местно-распространенного рака молочной железы	95
Atakhanov N.E., Almuradova D.M., Ziyayev Sh.V., Sagdullaeva S.N., Khamidov H., Sadullaeva N. Efficiency and toxicity of the intensified platinum-containing regimen in primary breast cancer with a triple negative phenotype	96
Бабаханова Д.С., Ибрагимов А.Ю., Мамадалиева Я.С. Ультразвуковой компонент профилактического осмотра рака молочной железы на уровне первичного звене здравоохранения	96
Бобоев Ш.Р., Аминжонов Р.М. Сут беги саратони диагностикасида онкомаркёрларнинг аҳамияти	97
Гафур-Ахунوف М.А., Мирзамухаммедов Х.К., Авезмуратова Г.А., Эгамбердиев Г.М. Результаты противоопухолевого лечения больных с метастатическим трижды негативным раком молочной железы	97

analyze. ER, PR, HER/2 and Ki-67 oncomarkers were evaluated.

Result. Distribution of immunohistochemical subtypes were studied in pre- and postmenopausal women according to BMI subgroup. In postmenopausal group Lyuminal A subtype more frequent obese patient than overweight and normal-weighted. Triple-negative histologic type more frequent in obese premenopausal women compared to postmenopausal and BMI < 30 kg/m² premenopausal. For premenopausal group, patients with BMI ≥ 30 kg/m² had ER and PR negative tumors compared with normal-weighted patient. Treatment characteristics. All of patients accepted neoadjuvant chemotherapy (AC – doxorubicin + cyclophosphamide and TP- paclitaxel + carboplatin) 6 or 8 course. Total of 34 patients underwent surgery. 5 of them were operated with breast conserving surgery, other with radical mastectomy on method Madden. Among BMI groups, no significant difference in relation to chemotherapy and surgery was found between pre- and postmenopausal patient. But premenopausal obese patients appeared to receive less hormonal therapy compared to postmenopausal obese patients (p < 0,001).

Conclusion. Obesity has been reported to be an adverse factor of survival BC patients, our research work indicated that higher BMI was found the independent predictor of BC mortality. Finally, there may be other risk factors for each immunohistochemical subtype independent of menopausal period and BMI.

METASTATIC BREAST CANCER IN MEN

Alimkhodzhaeva L.T.¹, Norbekova M.Kh.²

Republican specialized scientific and practical medical center of oncology and radiology¹, Tashkent Medical Academy²

Aim: Optimization of diagnostic and therapeutic measures with the assessment of prognostic factors in metastatic breast cancer in men.

Materials and research methods. To study the results of treatment of metastatic breast cancer (MBC) in the Republic of Uzbekistan covers the period from 2010 to 2020 (10 years), 103 patients with newly diagnosed breast cancer with metastases.

Results. The largest group consisted of patients with breast cancer with metastases in the age group of 41-50 years (31%) and 51-60 years (27.3%). There were slightly fewer patients with breast cancer at the age of 61-70 years (19.6%) and even fewer in the elderly - 79 patients (7.6%). The most common histological forms of the primary tumor were lobular (41%) and ductal (30%) types of cancer. In 13.5% of cases, the histological structure of the tumor was represented by an undifferentiated form, due in some cases to therapeutic pathomorphosis.

Conclusion. The size of neoplasms ranged from 0 to 5 cm or more. One-year survival of patients with MBC differed depending on the size of the primary tumor. Between groups of patients with sizes from 2 to 5 cm and more than 5 cm, the overall 5-year survival was not statistically significantly different (35% and 28%, respectively). It is noticeable that the 5-year survival rate of patients with metastatic breast cancer with tumors less than 2 cm was 66.9%, while with tumors more than 5 cm it was only 28.8% (P < 0.001). The upper outer quadrant, as well as the central part of the mammary gland, were statistically significantly more often (34.2 ± 4.87 and 46.1 ± 4.7 cases, respectively) affected by the tumor compared with the lower outer (5.7 ± 1.69), upper inner (7.5 ± 2.28) and lower inner (2.3 ± 0.94) quadrants. According to our study, the bones were already affected at the initial admission in 24.0% of cases. In 8 cases it was the spine, in 7 - the ribs and 4 - the ilium. Osteolytic lesions were noted in 5 patients. In two cases it was difficult to determine the type of lesion radiographically. Thus, 64.2% of patients survived 5 years or more, which was statistically significantly higher than with combined and combined methods (P < 0.05, t = 2.1). The main histological forms of breast cancer were lobular and ductal variants of the tumor, which together accounted for 71% of the forms.

Thus, in the treatment of metastatic breast cancer, it is necessary to provide adequate local treatment of the primary focus, control of metastatic regional and distant ones, which prevents further spread of the tumor process and leads to an increase in survival and improvement in the quality of life of patients. When choosing a method of treatment, it is necessary to take into account the localization of the metastasis, the age and general condition of the patient, her menstrual status, the presence of concomitant diseases, previous treatment for primary breast cancer. Important prognostic factors are the number of metastatic regional lymph nodes, the histological structure of the tumor, and the treatment methods used.